| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2140813 | Lung Cancer | 2013 | 7 Pages |
Abstract
In our case-control analysis in long-term erlotinib responders, treatment with TKI beyond progression in addition to chemotherapy or radiotherapy was feasible and lead to prolonged overall survival.
Keywords
EGFR tyrosine kinase inhibitorsTKIEGFRn.s.BSCPFsAdenocarcinomaErlotinibprogression-free survivaloverall survivalBest supportive carestable diseaseCase–control analysisEGFR mutationRECISTNSCLCNon-small cell lung cancerTreatment failure95% confidence intervalResponse Evaluation Criteria in Solid TumorsTyrosine kinase inhibitornot significanthazard ratioEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Faehling, R. Eckert, T. Kamp, S. Kuom, U. Griese, J. Sträter, G. Ott, W. Spengler,